

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF **SHIRIN FORD ET AL.**

**FOR: BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH
FACTOR RECEPTOR MODULATORS IN NON-SMALL CELL LUNG CANCER**

APPLICATION NO: **10/594211**

APPLICATION DATE: **03/28/2005**

ART UNIT: **1643**

EXAMINER:

CONFIRMATION NO: **6324**

USPTO CUSTOMER NO: **23914**

TRANSMITTED VIA EFS-WEB

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, Applicant directs the Examiner's attention to the references cited on the attached form(s) PTO/SB/08A.

These references were cited in a corresponding supplementary European Search Report. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing references in relation to this application and to indicate that each reference was considered by returning an initialed copy of the PTO/SB/08A form(s).

This Supplemental Information Disclosure Statement is believed to be submitted before the mailing of a first Office action on the merits and, accordingly, no fee is believed due. 37 C.F.R. §1.97(b)(3). If this belief is erroneous, please charge any requisite fees to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company

Statement under 37 C.F.R. §1.97(e)(1)


I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Statement under 37 C.F.R. §1.704(d)

I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Paul D. Golian
Attorney for Applicant
Reg. No. 42,591
Phone: 609-252-4091
Date: 10/14/08